In the wake of a U.S. Supreme Court decision that state tort claims against generic drug manufacturers are pre-empted by federal regulations, a U.S. district judge has ruled that the decision does not strengthen the hand of pharmaceutical manufacturers to remove lawsuits to federal court.

U.S. District Judge Berle M. Schiller ruled Tuesday that 19 lawsuits pending against generic drugmaker Mylan Inc. should be remanded to Philadelphia Common Pleas Court because a state court should decide their merits, including if the plaintiffs’ claims are pre-empted in the wake of the Supreme Court decision.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]